stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Gross margin
Novartis AG's gross margin over the twelve months to 30 September 2026 was 74.9%, down 0.9 percentage points from fiscal 2025 (75.8%). Over the past ten years it has ranged from 64.6% (fiscal 2016) to 75.8% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 75.8% | 0.63 |
| FY2024 | 75.2% | 1.93 |
| FY2023 | 73.3% | (0.08) |
| FY2022 | 73.4% | 3.36 |
| FY2021 | 70.0% | 0.29 |
| FY2020 | 69.7% | (0.67) |
| FY2019 | 70.4% | 1.85 |
| FY2018 | 68.5% | 2.78 |
| FY2017 | 65.7% | 1.18 |
| FY2016 | 64.6% | (0.90) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 76.0% | 0.80 |
| Jun 2026 | 75.2% | 0.77 |
| Mar 2026 | 74.4% | 0.47 |
| Dec 2025 | 74.0% | (1.40) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG | 74.9% |
| ABBV AbbVie Inc. compare | 73.7% |
| PFE Pfizer Inc. compare | 73.4% |
| MRK Merck & Co., Inc. compare | 71.8% |
| AMGN Amgen Inc. compare | 70.9% |
| JNJ Johnson & Johnson compare | 67.6% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement